CRISPR And Cas Genes Market Size, Share & Trends Report

CRISPR And Cas Genes Market Size, Share & Trends Analysis Report By Product & Service, By Application (Biomedical, Agricultural), By End-use (Biotechnology & Pharmaceutical Companies), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-1-68038-375-1
  • Number of Report Pages: 140
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2021
  • Forecast Period: 2023 - 2030 
  • Industry: Healthcare

Research Methodology

A three-pronged approach was followed for deducing the CRISPR and cas genes market estimates and forecasts. The process has three steps: information procurement, analysis, and validation. The whole process is cyclical, and steps repeat until the estimates are validated. The three steps are explained in detail below:

Information procurement: Information procurement is one of the most extensive and important stages in our research process, and quality data is critical for accurate analysis. We followed a multi-channel data collection process for CRISPR and cas genes market to gather the most reliable and current information possible.

  • We buy access to paid databases such as Hoover’s and Factiva for company financials, industry information, white papers, industry journals, SME journals, and more.
  • We tap into Grand View’s proprietary database of data points and insights from active and archived monitoring and reporting.
  • We conduct primary research with industry experts through questionnaires and one-on-one phone interviews.
  • We pull from reliable secondary sources such as white papers and government statistics, published by organizations like WHO, NGOs, World Bank, etc., Key Opinion Leaders (KoL) publications, company filings, investor documents, and more.
  • We purchase and review investor analyst reports, broker reports, academic commentary, government quotes, and wealth management publications for insightful third-party perspectives.

Analysis: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilized different methods of CRISPR and cas genes market data depending on the type of information we’re trying to uncover in our research.

  • Market Research Efforts: Bottom-up Approach for estimating and forecasting demand size and opportunity, top-down Approach for new product forecasting and penetration, and combined approach of both Bottom-up and Top-down for full coverage analysis.

  • Value-Chain-Based Sizing & Forecasting: Supply-side estimates for understanding potential revenue through competitive benchmarking, forecasting, and penetration modeling.

  • Demand-side estimates for identifying parent and ancillary markets, segment modeling, and heuristic forecasting.

  • Qualitative Functional Deployment (QFD) Modelling for market share assessment.

Market formulation and validation: We mine the data collected to establish baselines for forecasting, identify trends and opportunities, gain insight into consumer demographics and drivers, and so much more. We utilize different methods of data analysis depending on the type of information we’re trying to uncover in our research.

  • Market Formulation: This step involves the finalization of market numbers. This step on an internal level is designed to manage outputs from the Data Analysis step.

  • Data Normalization: The final market estimates and forecasts are then aligned and sent to industry experts, in-panel quality control managers for validation.

  • This step also entails the finalization of the report scope and data representation pattern.

  • Validation: The process entails multiple levels of validation. All these steps run in parallel, and the study is forwarded for publishing only if all three levels render validated results.

CRISPR And Cas Genes Market Categorization:

The CRISPR and cas genes market was categorized into four segments, namely product & service (By Product, By Service), application (Biomedical, Agricultural), end-use (Biotechnology & Pharmaceutical Companies, Academics & Government Research Institutes, Contract Research Organizations), and regions (North America, Europe, Asia Pacific, Latin America, Middle East & Africa).

Segment Market Methodology:

The CRISPR and cas genes market was segmented into product & service, application, end-use, and regions. The demand at a segment level was deduced using a funnel method. Concepts like the TAM, SAM, SOM, etc., were put into practice to understand the demand. We at GVR deploy three methods to deduce market estimates and determine forecasts. These methods are explained below:

Market research approaches: Bottom-up

  • Demand estimation of each product across countries/regions summed up to from the total market.

  • Variable analysis for demand forecast.

  • Demand estimation via analyzing paid database, and company financials either via annual reports or paid database.

  • Primary interviews for data revalidation and insight collection.

Market research approaches: Top-down

  • Used extensively for new product forecasting or analyzing penetration levels.

  • Tool used invoice product flow and penetration models Use of regression multi-variant analysis for forecasting Involves extensive use of paid and public databases.

  • Primary interviews and vendor-based primary research for variable impact analysis.

Market research approaches: Combined

  • This is the most common method. We apply concepts from both the top-down and bottom-up approaches to arrive at a viable conclusion.

Regional Market Methodology:

The CRISPR and cas genes market was analyzed at a regional level. The global was divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, keeping in focus variables like consumption patterns, export-import regulations, consumer expectations, etc. These regions were further divided into twenty-three countries, namely, the U.S.; Canada; Germany; the UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Thailand; Australia; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait.

All three above-mentioned market research methodologies were applied to arrive at regional-level conclusions. The regions were then summed up to form the global market.

CRISPR and cas genes market companies & financials:

The CRISPR and cas genes market was analyzed via companies operating in the sector. Analyzing these companies and cross-referencing them to the demand equation helped us validate our assumptions and conclusions. Key market players analyzed include:

  • AstraZeneca is a publicly owned pharmaceutical company that is involved in manufacturing and marketing primary care and specialty care medicines. The company focuses on three main areas, namely cardiovascular & metabolic diseases, respiratory, and oncology, as well as selectively in the areas of neuroscience, infectious diseases, and inflammation & autoimmunity. The company also focuses on emerging technologies, such as CRISPR genome editing and Modified RNA, in collaboration with several academic and biotechnology research institutions. The company operates in more than 100 countries across the world.

  • Addgene is a nonprofit organization involved in offering plasmids and other genome engineering solutions to researchers. It operates as a plasmid repository for research entities with over 70,000 plasmids, including special collections on fluorescent proteins, CRISPR, chemogenetics, viral plasmids, and optogenetics. Addgene also focuses on the development of educational resources, such as eBooks, blog posts, and protocols. Plasmids 101 and CRISPR 101 blog series by this organization help scientists in molecular biology, genome engineering, cloning, and other aspects.           

  • Caribou Biosciences, Inc. is a privately held company focusing on CRISPR-Cas genome editing. The company offers CRISPR-Cas9 technology-based medical therapies and bio-based products. The company also offers CRISPR-Cas gene-editing technology platforms for gene targeting to various service sectors, such as industrial biotechnology, agricultural biotechnology, biological research, and therapeutics. Novartis and Intellia Therapeutics are among the key collaborators of the company.

  • Cellectis is a public clinical-stage biopharmaceutical company having expertise in gene editing. The company’s proprietary gene-editing technologies, TALEN and PulseAgile electroporation technology, are used to develop various immunotherapy product candidates. TALEN, a registered trademark of the company, is a genome-editing technology used to develop CAR-T therapies. The company is present in Paris, France; New York; and Raleigh, North Carolina.   

  • CRISPR Therapeutics is a gene-editing company that manufactures and commercializes transformative therapeutics using CRISPR/Cas9 gene-editing platform. The company has established several therapeutic programs across a wide range of disease areas, such as oncology, hemoglobinopathies, rare diseases, and regenerative medicine. The company shares a partnership with Vertex Pharmaceuticals; ViaCyte, Inc.; and Bayer AG to expand its product portfolio. The company has its business offices in London, the UK, and San Francisco, California.

  • Editas Medicine, Inc. is a public genome editing company focused on developing medicines using genome editing platforms. It is involved in the development and commercialization of transformative medicines majorly for three therapeutic areas, namely ocular diseases, blood diseases, and cancer. The company has developed a genome editing platform based on CRISPR technology. The company uses CRISPR gene editing technology to develop new genomic medicines.     

  • eGenesis is a privately owned gene editing and genome engineering company that focuses on the development of safe & effective human transplantable tissues, organs, and cells. The company uses gene editing technology, such as CRISPR, to fulfill demands in the field of transplantation. The company’s lead program focuses on kidney transplantation, which is under clinical development. The company is also investigating additional indications, such as liver, islet cells, heart, and lung as well as cell therapies.

  • F. Hoffmann-La Roche Ltd. offers a broad range of diagnostic tests. The company’s diagnostics segment consists of clinical chemistry & immunoassay, urinalysis, hematology & hemostasis, molecular diagnostics, tissue diagnostics, and POC diagnostics. It also focuses on endemic diseases such as cancer, cardiology & metabolism, infectious diseases, inflammatory & autoimmune, women’s health, and critical care. The company is present in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Currently, Roche Group has 22 R&D sites and 26 manufacturing sites worldwide.

  • Horizon Discovery Group plc offers products, services, and research programs to clients engaged in healthcare research & development. The company has offices in the UK, Europe, and the U.S. It supplies research tools and expert services to more than 1,600 organizations involved in genomics R&D of personalized medicines globally. These organizations include biotechnology, pharmaceutical & diagnostic companies, and academic research centers. It offers products & services for cell line development, in vivo models, and bioproduction. Its research services portfolio includes functional genomic screening, immuno-oncology platform, in-vitro assay services, drug combination, and in-vivo assay services. It also provides services and products for Sanger & qPCR sequencing, immunohistochemistry, NGS, and FISH.

  • GenScript is a global biotechnology group of companies that focuses on gene synthesis technology. The company’s business comprises four major categories, which include life sciences CRO, biologics development & manufacturing, enzyme & synthetic biology products, and cell therapy. The company has an established presence in North America, Europe, Asia Pacific, and Greater China. Moreover, as reported in January 2019, the company was cited by around 36,500 scientific papers globally.

Value chain-based sizing & forecasting

Supply Side Estimates

  • Company revenue estimation via referring to annual reports, investor presentations, and Hoover’s.

  • Segment revenue determination via variable analysis and penetration modeling.

  • Competitive benchmarking to identify market leaders and their collective revenue shares.

  • Forecasting via analyzing commercialization rates, pipelines, market initiatives, distribution networks, etc.

Demand side estimates

  • Identifying parent markets and ancillary markets

  • Segment penetration analysis to obtain pertinent

  • revenue/volume

  • Heuristic forecasting with the help of subject matter experts

  • Forecasting via variable analysis

CRISPR And Cas Genes Market Report Objectives:

  • Understanding market dynamics (in terms of drivers, restraints, & opportunities) in the countries.

  • Understanding trends & variables in the individual countries & their impact on growth and using analytical tools to provide high-level insights into the market dynamics and the associated growth pattern.

  • Understanding market estimates and forecasts (with the base year as 2022, historic information from 2018 to 2021, and forecast from 2023 to 2030). Regional estimates & forecasts for each category are available and are summed up to form the global market estimates.

CRISPR And Cas Genes Market Report Assumptions:

  • The report provides market value for the base year 2022 and a yearly forecast till 2030 in terms of revenue/volume or both. The market for each of the segment outlooks has been provided on region & country basis for the above-mentioned forecast period.

  • The key industry dynamics, major technological trends, and application markets are evaluated to understand their impact on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis.

  • We have used the bottom-up approach for market sizing, analyzing key regional markets, dynamics, & trends for various products and end-users. The total market has been estimated by integrating the country markets.

  • All market estimates and forecasts have been validated through primary interviews with the key industry participants.

  • Inflation has not been accounted for to estimate and forecast the market.

  • Numbers may not add up due to rounding off.

  • Europe consists of EU-8, Central & Eastern Europe, along with the Commonwealth of Independent States (CIS).

  • Asia Pacific includes South Asia, East Asia, Southeast Asia, and Oceania (Australia & New Zealand).

  • Latin America includes Central American countries and the South American continent

  • Middle East includes Western Asia (as assigned by the UN Statistics Division) and the African continent.

Primary Research

GVR strives to procure the latest and unique information for reports directly from industry experts, which gives it a competitive edge. Quality is of utmost importance to us, therefore every year we focus on increasing our experts’ panel. Primary interviews are one of the critical steps in identifying recent market trends and scenarios. This process enables us to justify and validate our market estimates and forecasts to our clients. With more than 8,000 reports in our database, we have connected with some key opinion leaders across various domains, including healthcare, technology, consumer goods, and the chemical sector. Our process starts with identifying the right platform for a particular type of report, i.e., emails, LinkedIn, seminars, or telephonic conversation, as every report is unique and requires a differentiated approach.

We send out questionnaires to different experts from various regions/ countries, which is dependent on the following factors:

  • Report/Market scope: If the market study is global, we send questionnaires to industry experts across various regions, including North America, Europe, Asia Pacific, Latin America, and MEA.

  • Market Penetration: If the market is driven by technological advancements, population density, disease prevalence, or other factors, we identify experts and send out questionnaires based on region or country dominance.

The time to start receiving responses from industry experts varies based on how niche or well-penetrated the market is. Our reports include a detailed chapter on the KoL opinion section, which helps our clients understand the perspective of experts already in the market space.

What questions do you have? Get quick response from our industry experts. Request a Free Consultation



This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.



We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member


ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon